Active ingredient
- emtricitabine
- elvitegravir
- cobicistat
- tenofovir alafenamide fumarate
Legal Category
POM: Prescription only medicine
POM: Prescription only medicine
The Patient Information Leaflet (PIL) is the leaflet included in the pack with a medicine. It is written for patients and gives information about taking or using a medicine. It is possible that the leaflet in your medicine pack may differ from this version because it may have been updated since your medicine was packaged.
Below is a text only representation of the Patient Information Leaflet. The original leaflet can be viewed using the link above.
The text only version may be available in large print, Braille or audio CD. For further information call emc accessibility on 0800 198 5000. The product code(s) for this leaflet are: EU/1/15/1061/001, EU/1/15/1061/002.
Genvoya 150mg/150mg/200mg/10mg film coated tablets
Package leaflet: Information for the user
Genvoya 150 mg/150 mg/200 mg/10 mg film-coated tablets
elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
What is in this leaflet
1. What Genvoya is and what it is used for
2. What you need to know before you take Genvoya
3. How to take Genvoya
4. Possible side effects
5. How to store Genvoya
6. Contents of the pack and other information
If Genvoya has been prescribed for your child, please note that all the information in this leaflet is addressed to your child (in this case please read “your child” instead of “you”).
1. What Genvoya is and what it is used for
Genvoya contains four active substances:
Genvoya is a single tablet for the treatment of human immunodeficiency virus 1 (HIV-1) infection in adults, adolescents and children 6 years of age and older, who weigh at least 25 kg.
Genvoya reduces the amount of HIV in your body. This will improve your immune system and reduce the risk of developing illnesses linked to HIV infection.
2. What you need to know before you take Genvoya
Do not take Genvoya
Warnings and precautions
You must remain under the care of your doctor while taking Genvoya.
You can still pass on HIV when taking this medicine, although the risk is lowered by effective antiretroviral therapy. Discuss with your doctor the precautions needed to avoid infecting other people. This medicine is not a cure for HIV infection. While taking Genvoya you may still develop infections or other illnesses associated with HIV infection.
Talk to your doctor before taking Genvoya:
While you are taking Genvoya
Once you start taking Genvoya, look out for:
Although kidney problems have not been observed with Genvoya, there is a possibility that you may experience kidney problems when taking Genvoya over a long period of time (see Warnings and precautions).
Children and adolescents
Do not give this medicine to children aged 5 years or under, or weighing less than 25 kg regardless of age. The use of Genvoya in children aged 5 years or under has not yet been studied.
Other medicines and Genvoya
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Genvoya may interact with other medicines. As a result, the amounts of Genvoya or other medicines in your blood may be affected. This may stop your medicines from working properly, or may make any side effects worse. In some cases, your doctor may need to adjust your dose or check your blood levels.
Medicines that must never be taken with Genvoya:
Medicines used in treating hepatitis B infection:
You should not take Genvoya with medicines containing:
Other types of medicine:
Talk to your doctor if you are taking:
Pregnancy and breast-feeding
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Driving and using machines
Genvoya can cause dizziness. If you feel dizzy when taking Genvoya, do not drive or ride a bicycle and do not use any tools or machines.
Genvoya contains sodium
This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially ‘sodium-free’.
Genvoya contains lactose
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.
3. How to take Genvoya
Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.
The recommended dose is:
Adults: one tablet each day with food
Adolescents and children 6 years of age and older, who weigh at least 25 kg: one tablet each day with food
Due to the bitter taste, it is recommended not to chew or crush the tablet.
If you have difficulty swallowing the tablet whole, you can split it in half. Take both halves of the tablet one after the other to get the full dose. Do not store the split tablet.
Always take the dose recommended by your doctor. This is to make sure that your medicine is fully effective, and to reduce the risk of developing resistance to the treatment. Do not change the dose unless your doctor tells you to.
Do not take antacids or multivitamins at the same time as Genvoya. If you are taking medicines, oral supplements, antacids or laxatives containing minerals (such as magnesium, aluminium, calcium, iron, zinc), take them at least 4 hours before or at least 4 hours after Genvoya.
If you are on dialysis, take your daily dose of Genvoya following completion of dialysis.
If you take more Genvoya than you should
If you accidentally take more than the recommended dose of Genvoya you may be at increased risk of experiencing possible side effects with this medicine (see section 4, Possible side effects).
Contact your doctor or nearest emergency department immediately for advice. Keep the tablet bottle with you so that you can easily describe what you have taken.
If you forget to take Genvoya
It is important not to miss a dose of Genvoya.
If you do miss a dose:
If you vomit less than 1 hour after taking Genvoya, take another tablet with food.
Do not stop taking Genvoya
Do not stop taking Genvoya without talking to your doctor. Stopping Genvoya can seriously affect your response to future treatment. If Genvoya is stopped for any reason, speak to your doctor before you restart taking Genvoya tablets.
When your supply of Genvoya starts to run low, get more from your doctor or pharmacist. This is very important because the amount of virus may start to increase if the medicine is stopped for even a short time. The disease may then become harder to treat.
If you have both HIV infection and hepatitis B, it is especially important not to stop your Genvoya treatment without talking to your doctor first. You may require blood tests for several months after stopping treatment. In some patients with advanced liver disease or cirrhosis, stopping treatment is not recommended as this may lead to worsening of your hepatitis, which may be life-threatening.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
4. Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Possible serious side effects: tell a doctor immediately
Very common side effects
(may affect more than 1 in 10 people)
Common side effects
(may affect up to 1 in 10 people)
Uncommon side effects
(may affect up to 1 in 100 people)
Other effects that may be seen during HIV treatment
The frequency of the following side effects is not known (frequency cannot be estimated from the available data).
During HIV therapy there may be an increase in weight and in levels of blood lipids and glucose. This is partly linked to restored health and life style, and in the case of blood lipids sometimes to the HIV medicines themselves. Your doctor will test for these changes.
Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the
or search for MHRA Yellow Card in the Google Play or Apple App Store
By reporting side effects you can help provide more information on the safety of this medicine.
5. How to store Genvoya
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and bottle after {EXP}. The expiry date refers to the last day of that month.
Store in the original package in order to protect from moisture. Keep the bottle tightly closed.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
6. Contents of the pack and other information
What Genvoya contains
The active substances are elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide. Each Genvoya film-coated tablet contains 150 mg of elvitegravir, 150 mg of cobicistat, 200 mg of emtricitabine and tenofovir alafenamide fumarate equivalent to 10 mg of tenofovir alafenamide.
The other ingredients are
Tablet core:
Lactose (as monohydrate), microcrystalline cellulose (E460), croscarmellose sodium, hydroxypropyl cellulose (E463), silicon dioxide (E551), sodium lauryl sulfate, magnesium stearate.
Film-coating:
Polyvinyl alcohol (E1203), titanium dioxide (E171), polyethylene glycol (E1521), talc (E553b), indigo carmine aluminium lake (E132), iron oxide yellow (E172).
What Genvoya looks like and contents of the pack
Genvoya film-coated tablets are green, capsule-shaped tablets, debossed on one side with “GSI” and the number “510” on the other side of the tablet. Genvoya comes in bottles of 30 tablets (with a silica gel desiccant that must be kept in the bottle to help protect your tablets). The silica gel desiccant is contained in a separate sachet or canister and should not be swallowed.
The following pack sizes are available: outer cartons containing 1 bottle of 30 film-coated tablets and outer cartons containing 90 (3 bottles of 30) film-coated tablets. Not all pack sizes may be marketed.
Marketing Authorisation Holder
Manufacturer
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
This leaflet was last revised in 01/2022.
GEN-21-12747
280 High Holborn, London, WC1V 7EE, UK
+353 214 825 999 (Ireland)
+44 (0)203 681 4681
+44 (0)203 681 4500
08000 113 700 (UK)
+353 1 291 3580 (Ireland)